{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:56Z","timestamp":1781626076005,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deraya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Fluoresc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In order to determine the appropriate dosage of pirtobrutinib for treating mantle cell lymphoma that has returned or has not responded to prior treatment, a novel, straightforward, sensitive, and quick first spectrofluorometric approach has been devised. The technique uses 2% w\/v sodium dodecyl sulfate (SDS) as an anionic surfactant to micellarly increase the drug\u2019s natural fluorescence. Following excitation at 320\u00a0nm, the increased fluorescence intensity of pirtobrutinib was observed at 380\u00a0nm. An assay method for determining the researched drug was developed by analyzing the drug\u2019s interaction with SDS and taking advantage of the increased fluorescence intensity. With a detection limit of 8.66 ng mL\n                    <jats:sup>\u2212\u20091<\/jats:sup>\n                    and a quantitation limit of 26.23 ng mL\n                    <jats:sup>\u2212\u20091<\/jats:sup>\n                    , the relative fluorescence intensity-concentration graphs were rectilinear for the 30\u20131000 ng mL\n                    <jats:sup>\u2212\u20091<\/jats:sup>\n                    range. The results of the validation of the proposed analytical method in compliance with ICH standards were judged to be satisfactory. The suggested technique was effectively used for detection in tampered-with human plasma and pharmaceutical formulation. A number of assessment tools have lately been presented, as GAPI and AGREE.\n                  <\/jats:p>","DOI":"10.1007\/s10895-025-04646-8","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:26:44Z","timestamp":1766474804000},"page":"1755-1763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First Fluorescence Method for Native Quantification of Pirtobrutinib Used for Treatment of Cancer in its Market Form and Biological Fluids; Application of Greenness"],"prefix":"10.1007","volume":"36","author":[{"given":"Hesham","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Madian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazed","family":"Walid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mennatullah","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Sarea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feby","family":"Amgad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selem","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"4646_CR1","unstructured":"FDA (2023). Archived from the original on 28 January 2023"},{"issue":"1","key":"4646_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","volume":"30","author":"D Telaraja","year":"2024","unstructured":"Telaraja D, Kasamon YL, Collazo JS, Leong R, Wang K, Li P, Dahmane E, Yang Y, Earp J, Grimstein M (2024) FDA approval summary: Pirtobrutinib for relapsed or refractory mantle cell lymphoma. Clin Cancer Res 30(1):17\u201322","journal-title":"Clin Cancer Res"},{"issue":"47","key":"4646_CR3","doi-asserted-by":"publisher","first-page":"34868","DOI":"10.1039\/D4RA06299J","volume":"14","author":"MK Pavithra","year":"2024","unstructured":"Pavithra MK, Chaya G, Deepakumari HN, Revanasiddappa HD, Mohammed SJ, Majdi HS, Alsabhan AH, Ukkund SJ (2024) LC-MS\/MS characterization of Pirtobrutinib impurities and product degradation: stability studies. RSC Adv 14(47):34868\u201334882","journal-title":"RSC Adv"},{"key":"4646_CR4","unstructured":"Food UD Administration (2023) FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma"},{"issue":"5","key":"4646_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","volume":"12","author":"B Aslan","year":"2022","unstructured":"Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V (2022) Pirtobrutinib inhibits wild-type and mutant bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J 12(5):80","journal-title":"Blood Cancer J"},{"issue":"1","key":"4646_CR6","first-page":"62","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J (2023) Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood J Am Soc Hematol 142(1):62\u201372","journal-title":"Blood J Am Soc Hematol"},{"key":"4646_CR7","doi-asserted-by":"publisher","first-page":"204062072211016","DOI":"10.1177\/20406207221101697","volume":"13","author":"JL Jensen","year":"2022","unstructured":"Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC (2022) The potential of Pirtobrutinib in multiple B-cell malignancies. Therapeutic Adv Hematol 13:20406207221101697","journal-title":"Therapeutic Adv Hematol"},{"issue":"1","key":"4646_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X (2022) BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol 15(1):138","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4646_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX (2022) Mechanisms of resistance to noncovalent bruton\u2019s tyrosine kinase inhibitors. N Engl J Med 386(8):735\u2013743","journal-title":"N Engl J Med"},{"issue":"10277","key":"4646_CR10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397(10277):892\u2013901","journal-title":"Lancet"},{"issue":"9","key":"4646_CR11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2174\/0115734129344382241105074413","volume":"20","author":"MD Mazhavancheril","year":"2024","unstructured":"Mazhavancheril MD, Baheti K (2024) Development and validation of stability indicating RP-HPLC method for the estimation of Pirtobrutinib and characterization of its degradants by LC-MS. Curr Pharm Anal 20(9):1043\u20131055","journal-title":"Curr Pharm Anal"},{"issue":"2","key":"4646_CR12","first-page":"267","volume":"37","author":"BS Babu","year":"2025","unstructured":"Babu BS, Nalanda RB, Mondal S (2025) A novel bioanalytical method development and validation of Pirtobrutinib in rat plasma by LC-MS\/MS and its application to pharmacokinetic study. Acta Chromatogr 37(2):267\u2013275","journal-title":"Acta Chromatogr"},{"issue":"5","key":"4646_CR13","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1002\/bmc.70061","volume":"39","author":"Y Gando","year":"2025","unstructured":"Gando Y, Yasu T, Shimoda M, Tukada M (2025) High-Performance liquid Chromatography\u2013Ultraviolet assay for the determination of Pirtobrutinib levels in a patient with mantle cell lymphoma. Biomed Chromatogr 39(5):e70061","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"4646_CR14","first-page":"6626","volume":"54","author":"PR Sankar","year":"2025","unstructured":"Sankar PR, Ujwala V, Prasad PS, Rani JJ, Swathi B, Paparao N, Divya B, Babu PS (2025) Development and validation of RP-HPLC method for determination of Pirtobrutinib in bulk and pharmaceutical dosage form. Cuest Fisioter 54(4):6626\u20136643","journal-title":"Cuest Fisioter"},{"issue":"1","key":"4646_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13065-025-01424-2","volume":"19","author":"M Zhang","year":"2025","unstructured":"Zhang M, Wu J, Li J, Yin H, Hou M, Dong R (2025) Development of a novel UHPLC-MS\/MS method for quantitative analysis of Pirtobrutinib in rat plasma: application to Pharmacokinetic study. BMC Chem 19(1):50","journal-title":"BMC Chem"},{"key":"4646_CR16","unstructured":"I. ICH (2005)\u00a0Q2 (R1): Validation of analytical procedures: text and methodology. International conference on harmonization, Geneva 20: 1\u201313"},{"key":"4646_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka J (2018) A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181:204\u2013209","journal-title":"Talanta"},{"issue":"14","key":"4646_CR18","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2022","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski M (2022) AGREE - analytical greenness metric approach and software. Anal Chem 92(14):10076\u201310082","journal-title":"Anal Chem"}],"container-title":["Journal of Fluorescence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-025-04646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10895-025-04646-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-025-04646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:37:50Z","timestamp":1781624270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10895-025-04646-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1007\/s10895-025-04646-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7785280\/v1","asserted-by":"object"}]},"ISSN":["1573-4994"],"issn-type":[{"value":"1573-4994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}